BR112018067454A2 - regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica - Google Patents
regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônicaInfo
- Publication number
- BR112018067454A2 BR112018067454A2 BR112018067454A BR112018067454A BR112018067454A2 BR 112018067454 A2 BR112018067454 A2 BR 112018067454A2 BR 112018067454 A BR112018067454 A BR 112018067454A BR 112018067454 A BR112018067454 A BR 112018067454A BR 112018067454 A2 BR112018067454 A2 BR 112018067454A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- pulmonary disease
- chronic obstructive
- obstructive pulmonary
- dosage regimen
- Prior art date
Links
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title abstract 2
- 230000009798 acute exacerbation Effects 0.000 title abstract 2
- VGUSQKZDZHAAEE-UHFFFAOYSA-N 3-[5-amino-4-(3-cyanobenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC(C#N)=C1 VGUSQKZDZHAAEE-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2016/050636 WO2017153702A1 (en) | 2016-03-08 | 2016-03-08 | Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018067454A2 true BR112018067454A2 (pt) | 2019-01-15 |
Family
ID=55586330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018067454A BR112018067454A2 (pt) | 2016-03-08 | 2016-03-08 | regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10603306B2 (https=) |
| JP (1) | JP6741774B2 (https=) |
| KR (2) | KR102762199B1 (https=) |
| AU (1) | AU2016397047B2 (https=) |
| BR (1) | BR112018067454A2 (https=) |
| CA (1) | CA3016488C (https=) |
| MX (1) | MX385717B (https=) |
| RU (1) | RU2713203C1 (https=) |
| WO (1) | WO2017153702A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102762199B1 (ko) * | 2016-03-08 | 2025-02-07 | 메레오 바이오파마 1 리미티드 | 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 |
| GB201612238D0 (en) | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide |
| GB201612240D0 (en) | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
| JP7280627B2 (ja) * | 2017-12-11 | 2023-05-24 | メレオ バイオファーマ １ リミテッド | 慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用 |
| AU2018381874B2 (en) | 2017-12-11 | 2024-08-15 | Mereo Biopharma 1 Limited | Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| US6598603B1 (en) | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
| PL2298743T3 (pl) * | 2003-06-26 | 2013-02-28 | Novartis Ag | Inhibitory kinaz P38 na bazie 5-członowych heterocykli |
| TW201705980A (zh) | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| GB0409703D0 (en) | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
| US20050277602A1 (en) | 2004-05-21 | 2005-12-15 | Grunstein Michael M | Methods employing agonists of P38 map kinase for the treatment of asthma |
| CA2640665A1 (en) | 2006-02-10 | 2007-08-16 | Pfizer Products Inc. | Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives |
| GB0603684D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| WO2013139809A1 (en) * | 2012-03-20 | 2013-09-26 | Novartis Ag | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease |
| KR102762199B1 (ko) * | 2016-03-08 | 2025-02-07 | 메레오 바이오파마 1 리미티드 | 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 |
| BR112018067784A2 (pt) * | 2016-03-08 | 2019-01-15 | Mereo Biopharma 1 Ltd | regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias |
-
2016
- 2016-03-08 KR KR1020247020223A patent/KR102762199B1/ko active Active
- 2016-03-08 KR KR1020187026084A patent/KR20180118667A/ko not_active Ceased
- 2016-03-08 CA CA3016488A patent/CA3016488C/en active Active
- 2016-03-08 JP JP2018547431A patent/JP6741774B2/ja active Active
- 2016-03-08 RU RU2018132047A patent/RU2713203C1/ru active
- 2016-03-08 AU AU2016397047A patent/AU2016397047B2/en active Active
- 2016-03-08 WO PCT/GB2016/050636 patent/WO2017153702A1/en not_active Ceased
- 2016-03-08 US US16/082,765 patent/US10603306B2/en active Active
- 2016-03-08 MX MX2018010782A patent/MX385717B/es unknown
- 2016-03-08 BR BR112018067454A patent/BR112018067454A2/pt not_active Application Discontinuation
-
2020
- 2020-02-18 US US16/793,922 patent/US11129810B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6741774B2 (ja) | 2020-08-19 |
| AU2016397047B2 (en) | 2022-04-07 |
| CA3016488A1 (en) | 2017-09-14 |
| MX2018010782A (es) | 2019-01-10 |
| KR20240101698A (ko) | 2024-07-02 |
| US10603306B2 (en) | 2020-03-31 |
| US20200281896A1 (en) | 2020-09-10 |
| AU2016397047A1 (en) | 2018-09-06 |
| JP2019507786A (ja) | 2019-03-22 |
| US20190060279A1 (en) | 2019-02-28 |
| RU2713203C1 (ru) | 2020-02-04 |
| CA3016488C (en) | 2023-04-11 |
| MX385717B (es) | 2025-03-18 |
| US11129810B2 (en) | 2021-09-28 |
| KR20180118667A (ko) | 2018-10-31 |
| WO2017153702A1 (en) | 2017-09-14 |
| KR102762199B1 (ko) | 2025-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264210A (en) | High-strength oral cannabinoid dosage forms | |
| BR112018067454A2 (pt) | regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica | |
| ZA201800022B (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| CL2018002727A1 (es) | Medicina obtenida mediante la combinación de agonista fxr y arb | |
| MX2017009449A (es) | Inhibidor jak. | |
| BR112017027843A2 (pt) | formulações farmacêuticas compreendendo tenofovir e emtricitabina | |
| UY39706A (es) | Derivados de (1hindol- 3-il)-2-(4-cloro-2-metoxi-fenil)-2-((3-metoxi-5-(metilsulfonil) fenil)amino)etanona como inhibidores de la replicación del virus del dengue | |
| AR096543A1 (es) | INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES | |
| MX386808B (es) | Sistema de suministro de fármaco que comprende un resto de hidrazona y un enlace amida para proporcionar liberción controlada de agentes terapéuticos | |
| PH12014502107B1 (en) | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease | |
| BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
| AR100663A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
| PH12019501955A1 (en) | Tri-cycle compound and applications thereof | |
| SV2016005313A (es) | Derivados de carboxamida | |
| CY1123576T1 (el) | Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib | |
| CY1122755T1 (el) | Eξισορροπημενες απο αποψη φυσιολογιας ενεσιμες μορφοποιησεις φωσνετουπιταντης | |
| BR112018067784A2 (pt) | regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias | |
| MY182008A (en) | Pharmaceutical formulations | |
| MX2016016491A (es) | Derivados de o-alquil-bencilidenguanidina y uso terapeutico para el tratamiento de trastornos asociados con acumulacion de proteinas mal plegadas. | |
| MX381526B (es) | Agente para suprimir el progreso de o para mejorar la enfermedad renal crónica. | |
| HK1245131A1 (zh) | 用於治疗炎症性疾病的包含十六酰胺乙醇pea和番茄红素的组合物 | |
| BR112018003335A2 (pt) | composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona | |
| EA201692013A1 (ru) | Новое применение n,n-бис-2-меркаптоэтил-изофталамида | |
| EP3375456A4 (en) | TOPICALLY APPLIED MEDICINE WITH DELAYED RELEASE | |
| IN2014CH00149A (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |